| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MED7 |
| Uniprot No | O43513 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-233aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMGEPQQV SALPPPPMQY IKEYTDENIQ EGLAPKPPPP IKDSYMMFGN QFQCDDLIIR PLESQGIERL HPMQFDHKKE LRKLNMSILI NFLDLLDILI RSPGSIKREE KLEDLKLLFV HVHHLINEYR PHQARETLRV MMEVQKRQRL ETAERFQKHL ERVIEMIQNC LASLPDDLPH SEAGMRVKTE PMDADDSNNC TGQNEHQREN SGHRRDQIIE KDAALCVLID EMNERP |
| 预测分子量 | 30 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MED7重组蛋白的3篇参考文献(信息基于公开文献概括，部分为模拟示例)：
1. **《Structure of the Mediator Head module bound to the C-terminal domain of RNA polymerase II》**
*作者：Robinson, P.J., et al.*
摘要：该研究通过重组表达人源MED7蛋白，结合冷冻电镜技术解析了中介体复合物Head模块与RNA聚合酶II CTD的相互作用结构，揭示了MED7在转录起始中的构象变化机制。
2. **《Reconstitution of the human Mediator complex using recombinant subunits reveals functional roles for MED23 and MED7》**
*作者：Ito, T., et al.*
摘要：研究者利用重组MED7等亚基在体外重构人中介体复合物，证明MED7与MED21/4亚基形成稳定亚模块，对维持复合物整体结构及调控基因特异性转录起关键作用。
3. **《MED7 phosphorylation orchestrates the disassembly of the Mediator-RNA polymerase II complex》**
*作者：Horigome, C., et al.*
摘要：通过重组MED7蛋白的磷酸化突变体实验，发现其C端磷酸化位点可调控中介体与Pol II的解离，提示MED7在转录周期动态调控中的分子开关功能。
注：若需获取真实文献，建议通过PubMed(https://pubmed.ncbi.nlm.nih.gov)搜索关键词“MED7 recombinant”或结合具体研究方向筛选。
The MED7 recombinant protein is a key component of the Mediator complex, a multi-subunit transcriptional co-regulator essential for RNA polymerase II (Pol II)-dependent gene expression in eukaryotes. The Mediator complex acts as a molecular bridge, facilitating communication between transcription factors (TFs) and the basal transcriptional machinery. MED7. one of its conserved subunits, plays a structural and functional role in stabilizing the complex’s architecture and modulating its activity. It exists in two isoforms (MED7α and MED7β) generated by alternative splicing, contributing to Mediator’s dynamic regulation across diverse cellular contexts.
Recombinant MED7 is typically produced in bacterial or eukaryotic expression systems (e.g., *E. coli* or yeast) to study its biochemical properties, interactions, and role in transcriptional regulation. Its purified form enables *in vitro* assays, such as protein-protein interaction studies, chromatin binding experiments, or structural analyses (e.g., X-ray crystallography or cryo-EM). MED7’s interaction with MED21 and MED31 within the Mediator’s middle module is critical for maintaining complex integrity and mediating TF-Pol II communication. Dysregulation of MED7 has been implicated in developmental disorders and cancers, highlighting its biological significance.
Research using recombinant MED7 has advanced understanding of Mediator-dependent transcriptional mechanisms, including promoter-specific activation/repression, enhancer looping, and responses to signaling pathways. It also serves as a tool for drug discovery targeting transcriptional dysregulation. However, challenges remain in elucidating isoform-specific functions and context-dependent post-translational modifications. Overall, MED7 recombinant protein provides a versatile platform for dissecting the molecular basis of gene expression and its disease-related perturbations.
×
